Bicycle Therapeutics (NASDAQ: BCYC) announced on Wednesday that it presented its first human imaging data at the EANM 2024 Congress, confirming the potential of MT1-MMP as a new target for cancer treatment. Data validated the effectiveness of Bicycle Radionuclide Conjugates (BRC) in targeting tumors, highlighting the BRC tracer's precision in primary and metastatic cancer sites with minimal off-target impact.

Preclinical studies presented showed that BRC biodistribution can be optimised to sustain high tumour uptake while reducing kidney retention. These findings demonstrate BRCs' ability to deliver radioisotopes such as indium, lutetium, and lead effectively to cancer cells, enhancing their potential in radiopharmaceuticals.

As part of its strategy to lead in next-generation radiopharmaceuticals, Bicycle Therapeutics has chosen EphA2 as a new BRC target. A letter of intent with Eckert & Ziegler aims to secure a reliable radioisotope supply and advance BRC manufacturing. The partnership aligns with Bicycle's strategy to exploit its proprietary bicyclic peptide technology, characterised by low molecular weight, rapid clearance, and high target affinity.

Data from EANM showcased the accuracy of MT1-MMP-targeted imaging in a case of advanced non-small cell lung cancer, mirroring results from traditional imaging while providing clearer differentiation at early time points. These outcomes underscore Bicycle's capacity to translate preclinical success into clinical applications.

Bicycle Therapeutics, headquartered in Cambridge, UK, with operations in Cambridge, Massachusetts, is focused on advancing a new class of constrained peptide-based therapeutics. The company is pursuing a robust pipeline, including investigational treatments for cancers traditionally resistant to existing therapies.